Principal Financial Group Inc Blueprint Medicines Corp Transaction History

Principal Financial Group Inc

$1.66 Trillion
Q3 2024

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 31, 2024	SELL	$84.1 - $120.5 $3.97 Million - $5.68 Million	-47,153 Reduced 81.03%	11,038 $1.02 Million
Q2 2024 Jul 29, 2024	SELL	$85.18 - $108.78 $381,521 - $487,225	-4,479 Reduced 7.15%	58,191 $6.27 Million
Q1 2024 Apr 29, 2024	BUY	$73.17 - $99.79 $3.52 Million - $4.81 Million	48,160 Added 331.91%	62,670 $5.94 Million
Q4 2023 Feb 07, 2024	BUY	$43.96 - $92.84 $10,858 - $22,931	247 Added 1.73%	14,510 $1.34 Million
Q3 2023 Nov 02, 2023	SELL	$46.9 - $66.0 $22,183 - $31,218	-473 Reduced 3.21%	14,263 $716,000
Q2 2023 Aug 07, 2023	SELL	$42.2 - $66.37 $11,520 - $18,119	-273 Reduced 1.82%	14,736 $931,000
Q1 2023 May 09, 2023	SELL	$37.97 - $50.0 $37,590 - $49,500	-990 Reduced 6.19%	15,009 $675,000
Q4 2022 Feb 09, 2023	BUY	$41.06 - $66.48 $16,136 - $26,126	393 Added 2.52%	15,999 $700,000
Q3 2022 Nov 09, 2022	SELL	$49.93 - $77.7 $21,270 - $33,100	-426 Reduced 2.66%	15,606 $1.03 Million
Q2 2022 Aug 10, 2022	SELL	$45.23 - $70.15 $44,642 - $69,238	-987 Reduced 5.8%	16,032 $809,000
Q1 2022 May 09, 2022	BUY	$54.1 - $110.08 $18,339 - $37,317	339 Added 2.03%	17,019 $1.09 Million
Q4 2021 Feb 09, 2022	SELL	$94.25 - $115.99 $644,293 - $792,907	-6,836 Reduced 29.07%	16,680 $1.79 Million
Q3 2021 Nov 09, 2021	BUY	$80.98 - $109.47 $60,573 - $81,883	748 Added 3.29%	23,516 $2.42 Million
Q2 2021 Aug 10, 2021	SELL	$82.78 - $101.0 $4.05 Million - $4.94 Million	-48,878 Reduced 68.22%	22,768 $2 Million
Q1 2021 May 10, 2021	BUY	$90.71 - $108.28 $4.18 Million - $4.99 Million	46,079 Added 180.23%	71,646 $6.97 Million
Q4 2020 Feb 08, 2021	BUY	$92.08 - $124.48 $626,051 - $846,339	6,799 Added 36.23%	25,567 $2.87 Million
Q3 2020 Nov 06, 2020	SELL	$66.45 - $92.7 $56,748 - $79,165	-854 Reduced 4.35%	18,768 $1.74 Million
Q2 2020 Aug 05, 2020	BUY	$57.09 - $79.27 $299,722 - $416,167	5,250 Added 36.53%	19,622 $1.53 Million
Q1 2020 May 12, 2020	BUY	$48.11 - $82.22 $37,189 - $63,556	773 Added 5.68%	14,372 $840,000
Q4 2019 Feb 05, 2020	SELL	$66.73 - $82.59 $43,708 - $54,096	-655 Reduced 4.6%	13,599 $1.09 Million
Q3 2019 Nov 13, 2019	BUY	$72.9 - $101.41 $99,800 - $138,830	1,369 Added 10.62%	14,254 $1.05 Million
Q2 2019 Aug 12, 2019	BUY	$73.54 - $97.8 $38,167 - $50,758	519 Added 4.2%	12,885 $1.22 Million
Q1 2019 May 10, 2019	BUY	$48.7 - $86.6 $28,635 - $50,920	588 Added 4.99%	12,366 $990,000
Q4 2018 Feb 14, 2019	SELL	$45.57 - $74.26 $133,155 - $216,987	-2,922 Reduced 19.88%	11,778 $635,000
Q3 2018 Nov 14, 2018	BUY	$58.91 - $78.32 $122,297 - $162,592	2,076 Added 16.44%	14,700 $1.15 Million
Q2 2018 Aug 13, 2018	SELL	$60.96 - $101.18 $16,154 - $26,812	-265 Reduced 2.06%	12,624 $0
Q1 2018 May 14, 2018	BUY	$73.28 - $102.95 $32,023 - $44,989	437 Added 3.51%	12,889 $1.18 Million
Q4 2017 Feb 13, 2018	BUY	$62.91 - $88.32 $404,196 - $567,456	6,425 Added 106.6%	12,452 $939,000
Q3 2017 Nov 02, 2017	BUY	$42.37 - $69.67 $255,363 - $419,901	6,027	6,027 $420,000

Others Institutions Holding BPMC

# of Institutions

351

Shares Held

60.3M

Call Options Held

2.25M

Put Options Held

1.18M

Vanguard Group Inc Valley Forge, PA

6.68M
Shares

$612 Million
0.01% of portfolio
Black Rock Inc. New York, NY

6.65M
Shares

$609 Million
0.02% of portfolio
Price T Rowe Associates Inc Baltimore, MD

5.39M
Shares

$494 Million
0.06% of portfolio
Wellington Management Group LLP Boston, MA

3.96M
Shares

$363 Million
0.07% of portfolio
State Street Corp Boston, MA

2.77M
Shares

$253 Million
0.01% of portfolio

View Full List

About Blueprint Medicines Corp

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.47B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

More about BPMC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.

Account